ESSITY B: Neutral View As Discount Rates Rise And Tissue Review Progresses

Essity’s updated analyst price target has been trimmed by about SEK 1 to around SEK 265, as analysts factor in slightly higher discount rates alongside only modest adjustments to revenue growth, profit margin and future P/E assumptions, following a series of recent target cuts and a downgrade across the Street.

Analyst Commentary

Recent research updates cluster around a more cautious stance, with several firms trimming price targets and JPMorgan moving to a downgrade. The focus is less on dramatic changes to Essity’s fundamentals and more on recalibrating what analysts are willing to pay for the stock through their P/E and discount rate assumptions.

Bullish and bearish analysts are looking at the same set of inputs, but drawing different conclusions about how much execution risk and slower growth assumptions should weigh on valuation.

Bullish Takeaways

Bullish analysts appear to see Essity’s underlying business profile as intact, given that several price target cuts, such as the SEK 5 and SEK 10 trims, are relatively small in absolute terms and framed as fine tuning rather than a fundamental reset.
Some support still comes from the view that modest revenue growth and margin assumptions can justify a mid tier P/E, even if the multiple is now being set a bit lower to reflect higher discount rates.
The fact that price targets are adjusted by SEK 5 to SEK 15 in stages suggests bullish analysts remain comfortable using incremental changes to their models rather than applying a steep valuation discount all at once.
For investors, this implies a research backdrop where Essity is still seen as investable, with the debate centered on what constitutes a fair entry multiple rather than on existential concerns about the business.

Bearish Takeaways

The downgrade at JPMorgan, combined with target cuts of SEK 15 and SEK 25 across the Street, signals that bearish analysts now see a higher risk that Essity may not fully deliver on prior growth or margin expectations.
Lowered price targets point to reduced confidence in how much investors should pay for future earnings, with bearish analysts building in higher discount rates and more conservative P/E assumptions.
Some bearish views likely reflect concern around Essity’s ability to execute against previous profit margin targets, which can weigh on earnings visibility and justify a lower valuation ceiling.
The clustering of target reductions in a short period suggests that bearish analysts view the prior consensus as too optimistic, and are resetting expectations to avoid potential downside if revenue growth or margins come in below earlier forecasts.

What's in the News

Essity's Board of Directors has started a review of the Consumer Tissue business area to assess different ownership options, which could include a potential separation, as part of efforts to optimize the product portfolio and long term value creation. Source: company announcement, comments by President and CEO Ulrika Kolsrud.
The Consumer Tissue unit, which includes Essity's own brands, retailer brands and private label products, is highlighted by management as having leading market positions and an efficient supply chain, factors that will be considered in the ongoing review. Source: company announcement, Ulrika Kolsrud.
At the Annual General Meeting on March 26, 2026, Essity declared a dividend of SEK 8.75 per share for the 2025 financial year, with a record date set for March 30, 2026. Source: AGM resolution.

Valuation Changes

Fair Value: SEK 266.21 to around SEK 265.07, a small trim of roughly 0.4% in the modelled fair value per share.
Discount Rate: 5.224% to 5.344%, a modest upward move that slightly raises the hurdle rate applied to future cash flows.
Revenue Growth: 2.33% to about 2.67%, a limited adjustment that reflects a slightly higher assumed top line growth rate in the model.
Net Profit Margin: 9.68% to about 9.70%, essentially unchanged with only a marginal tweak in the profitability assumption.
Future P/E: 14.16x to around 14.13x, a very small reduction in the valuation multiple applied to forward earnings.

2 views

Key Takeaways

Strong demand in incontinence, medical, and feminine care products, coupled with innovation and brand investments, supports sustained revenue and margin growth globally.
Focus on sustainability, premiumization, and ongoing cost-efficiency efforts positions Essity to benefit from changing consumer preferences and improved operating leverage.
Structural volume and margin pressures across key segments, rising costs, and increased competition threaten Essity's growth, profitability, and pricing power in core and emerging markets.

Catalysts

About Essity

Develops, produces, and sells hygiene and health products and services in Europe, North and Latin America, Asia, and internationally.What are the underlying business or industry changes driving this perspective?

The company continues to benefit from high and growing demand in incontinence and medical products, supported by an aging global population, which is driving stable long-term volume and revenue growth in these strategic categories.
Essity is experiencing strong growth in Feminine Care and Incontinence Retail segments across multiple geographies, leveraging rising healthcare standards and expanding middle class in emerging markets, supporting expectations of international revenue expansion.
Innovations in premium, eco-friendly, and coreless products-along with industry recognition for sustainability-position Essity to capitalize on shifting consumer preference for sustainable and higher-value tissue and hygiene products, which supports both topline growth and margin expansion.
Investment in brand building and marketing, as demonstrated by recent awards and increased A&P spend, is expected to drive greater brand loyalty and premiumization, bolstering future sales and improving net margins.
Ongoing cost-efficiency initiatives (supply chain savings, planned SG&A reductions, digitalization) are set to enhance operating leverage and protect net margins, especially as the company aims to return to higher volume growth in the face of stabilized input costs.

Essity Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Essity's revenue will grow by 2.7% annually over the next 3 years.
Analysts assume that profit margins will increase from 9.1% today to 9.7% in 3 years time.
Analysts expect earnings to reach SEK 14.3 billion (and earnings per share of SEK 21.35) by about June 2029, up from SEK 12.5 billion today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 14.1x on those 2029 earnings, up from 14.0x today. This future PE is lower than the current PE for the GB Household Products industry at 22.4x.
Analysts expect the number of shares outstanding to decline by 1.31% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 5.34%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent weak volume growth in key segments, particularly in Health & Medical and Baby Care, combined with limited ability to stimulate volumes in a challenging macroeconomic environment, poses a risk of structurally lower revenue growth than anticipated.
Rising SG&A costs, notably personnel and IT expenses, paired with insufficient volume growth to absorb these increases, have led to margin contraction and may continue to pressure net margins if costs are not adequately controlled.
Ongoing high promotional pressure and aggressive price competition, especially in segments like Baby Care and lower/mid-tier Consumer Tissue, may erode Essity's pricing power and gross margins, particularly if private label and low-cost competitors continue gaining share.
Sustained weakness in Professional Hygiene, exacerbated by structural shifts such as reduced restaurant and hotel traffic in North America and Europe, suggests lasting lower demand for away-from-home products, potentially limiting revenue and operating leverage in that segment.
Exposure to input cost volatility-including raw materials, tariffs (notably on U.S.-to-Canada exports), and distribution expenses-without commensurate ability to fully pass through these costs in all geographies and segments, could constrain earnings and net margin expansion, especially as industry consolidation intensifies pressure from retailers and distributors.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of SEK265.07 for Essity based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK300.0, and the most bearish reporting a price target of just SEK215.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK147.9 billion, earnings will come to SEK14.3 billion, and it would be trading on a PE ratio of 14.1x, assuming you use a discount rate of 5.3%.
Given the current share price of SEK255.9, the analyst price target of SEK265.07 is 3.5% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Essity?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analysts Cite Trough Valuation and Limited Catalysts as Essity Price Targets Edge Lower